Coherus BioSciences

62 articles with Coherus BioSciences

• Vizient Applauds FDA Approval of Biosimilar UDENYCA

  11/5/2018

  Vizient announces its support for the approval of UDENYCA™ (pegfilgrastim-cbqv), the second pegfilgrastim biosimilar approved by the Food and Drug Administration (FDA) and the first to be authorized by both the U.S. and the European Commission for patients with cancer receiving myelosuppressive chemotherapy.

• 

  Drugs That Are Likely to Fall Off the Patent Cliff This Year

  4/5/2018

  If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
• 

  The Biggest Winners and Losers of JPM 2018

  1/17/2018

  With the J.P. Morgan Healthcare Conference now over, some analysts are looking back and picking out the "winners and losers" from the conference.

• Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results

  11/7/2017

  The company reported financial results and reviewed corporate events for the third quarter ended September 30, 2017.

• Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th

  10/23/2017

  Starting at 4:30 p.m. EDT, Coherus' management will host a conference call to discuss the financial results and provide a general business update.

• Coherus Provides Update On ‘619 IPR Institution Decision

  9/8/2017

• Coherus Announces Positive Topline Results For Clinical Pharmacokinetic Bioequivalence Study For CHS-1420 (Humira® Biosimilar Candidate) Versus European Marketed Humira In Healthy Subjects

  8/28/2017

• Coherus Secures Private Placement From Temasek

  8/21/2017

• Coherus Reports Second Quarter 2017 Corporate Highlights And Financial Results

  8/8/2017

• Coherus Files Petition For Inter Partes Review Of ENBREL Patent 8,163,522

  8/7/2017

• Coherus To Report Second Quarter 2017 Financial Results On August 7th

  7/24/2017

• Bay Area's Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug

  7/6/2017

• After FDA Rejection, Bay Area's Coherus Axes 30% of Employees

  6/29/2017

• Bay Area's Coherus Craters After the FDA Spurns Its Biosimilar for Amgen's Neulasta

  6/13/2017

• Coherus Prevails In ‘135 IPR Decision

  5/17/2017

• Coherus Reports First Quarter 2017 Corporate Highlights And Financial Results

  5/9/2017

• Coherus Completes Patent Dance Exchange With Amgen For Neulasta Biosimilar

  4/25/2017

• Coherus To Report First Quarter 2017 Financial Results On May 8th

  4/24/2017

• Amgen Files Trade Secret Action Against Bay Area's Coherus

  3/7/2017

• Coherus Announces Proposed Public Offering Of Common Stock

  2/8/2017